Earnings & Valuation
This table compares the financial performance of ADMA Biologics and Passage Bio.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADMA Biologics | $330.24 million | 10.96 | -$28.24 million | ($0.02) | -781.00 |
| Passage Bio | N/A | N/A | -$102.06 million | ($1.53) | -0.38 |
ADMA Biologics has higher revenue and better earnings than Passage Bio and is currently a more affordable stock based on its price-to-earnings ratio.
Risk & Volatility
ADMA Biologics has a beta of 0.62, making it less volatile than the S&P 500, while Passage Bio has a beta of 1.19, indicating it is more volatile.
Analyst Recommendations
Here’s a summary of analyst ratings for both companies:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADMA Biologics | 0 | 0 | 3 | 1 | 3.25 |
| Passage Bio | 0 | 0 | 3 | 0 | 3.00 |
ADMA Biologics has a price target of $15.50, while Passage Bio’s is $8.33, suggesting Passage Bio has a much higher potential upside.
Profitability
Comparison of profitability between ADMA Biologics and Passage Bio:
| Net Margins | Return on Equity | Return on Assets | |
| ADMA Biologics | 10.53% | 38.79% | 17.35% |
| Passage Bio | N/A | -70.74% | -52.29% |
Insider and Institutional Ownership
ADMA Biologics has 75.7% of its shares owned by institutional investors, compared to 53.5% for Passage Bio. 3.7% of ADMA shares are owned by insiders, while Passage Bio has 4.3% insider ownership. High institutional ownership suggests confidence in long-term growth.
Summary
ADMA Biologics outperforms Passage Bio in 9 out of 13 comparative factors.
About ADMA Biologics
ADMA Biologics, based in Ramsey, NJ, develops plasma-derived therapies for immune deficiencies and infectious diseases.
About Passage Bio
Passage Bio, based in Philadelphia, PA, focuses on gene therapies for central nervous system diseases.
Receive News & Ratings for ADMA Biologics Daily – Enter your email below for daily summaries of news and ratings for ADMA Biologics via MarketBeat.com’s FREE newsletter.
`
